Organogenesis
Update in progressORGO (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
Organogenesis Holdings Inc. is a regenerative medicine company that develops, manufactures, and markets products for advanced wound care, surgical, and sports medicine in the United States. Its portfolio includes amnion/chorion placental allografts (Affinity, Novachor), Apligraf, Dermagraft, NuShield, PuraPly AM/SX, CYGNUS Dual/VIA Matrix/SimpliMax, PuraPly MZ, PuraForce, FortiShield, TransCyte, and ReNu (Phase 3) for knee osteoarthritis. Headquartered in Canton, MA, it serves hospitals, wound care centers, and clinics via direct and partner channels.
Company score
- Sentiment
- 0.53
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.19
- Governance
- 0.12
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.08
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.31
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!